title: The Clinical and Economic Impact of the V-Go®Disposable Insulin Delivery Device for Insulin Delivery in Patients with Poorly Controlled Diabetes at High Risk.
abstract: BACKGROUND
  Diabetes is a chronic condition and when poorly controlled can lead to complications and death. Patients with glycated hemoglobin (A1C) measures >9 % are at significant risk for diabetes-related complications impacting the patient's quality of life and imposing higher costs on the healthcare system. A1C reductions of 1 % or greater in this population have demonstrated substantial health and economic benefits. Reducing the percent of patients at risk is an essential component of quality-care measures established for patients with diabetes.
  
  
  OBJECTIVE
  To evaluate if switching patients prescribed subcutaneous insulin injections to V-Go for insulin delivery would impact clinical and economic parameters in patients with poorly controlled diabetes (A1C > 9 %).
  
  
  METHODS
  The study was a retrospective analysis using data extracted from the electronic medical records database of a multicenter diabetes system. Outcome measures included mean change in A1C from baseline, the percent of patients achieving a reduction in A1C ≥1 % while on V-Go therapy, and the impact to quality measures. In addition, economic analyses were conducted to assess the pharmacy budget impact and projected implication to total healthcare cost.
  
  
  RESULTS
  Ninety-seven patients were evaluated after a mean duration of 13.6 ± 6.9 weeks of insulin delivery with V-Go. Switching to V-Go resulted in an overall mean change (95 % CI) in A1C of -2.0 % (-1.7 to -2.3;p< 0.001) from a baseline of 10.5 %. Seventy-three percent of patients achieved an A1C reduction ≥1 %. Cost analysis supported a direct pharmacy savings of $119.30 (18.80-219.60,p= 0.020) per patient per month compared with baseline.
  
  
  CONCLUSIONS
  Switching to V-Go for insulin delivery resulted in significant glycemic improvement and proved cost effective. This real-world assessment could be applied more broadly at the health system and plan level.
authors.affiliation: Diabetes America, 1708 Coit Rd, Ste 100, Plano, TX 75075 USA.
authors.forename: Rosemarie
authors.initials: R
authors.lastname: Lajara
authors.affiliation: Valeritas, Inc., 750 Route 202, Suite 600, Bridgewater, NJ 08807 USA.
authors.forename: Carla
authors.initials: C
authors.lastname: Nikkel
authors.affiliation: Valeritas, Inc., 750 Route 202, Suite 600, Bridgewater, NJ 08807 USA.
authors.forename: Scott
authors.initials: S
authors.lastname: Abbott